Scotiabank raised the firm’s price target on Bio-Techne (TECH) to $88 from $83 and keeps an Outperform rating on the shares. The company continued to see stabilization for biopharma, with early indications of improvement in biotech, the analyst tells investors. While the company did not provide guidance, 1H revenues are expected to grow in the mid-single digits and 2H topline outlook remains gradual acceleration, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH:
- Bio-Techne price target raised to $84 from $82 at Baird
- Bio-Techne Reports First Quarter Fiscal 2025 Results
- Early notable gainers among liquid option names on October 30th
- Bio-Techne reports Q1 adjusted EPS 42c, consensus 38c
- TECH Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
